Table 1.
Baseline characteristics
| Start antiplatelet therapy (n=268) | Avoid antiplatelet therapy (n=269) | |||
|---|---|---|---|---|
| Sex | ||||
| Male | 173 (65%) | 187 (70%) | ||
| Female | 95 (35%) | 82 (30%) | ||
| Age* | ||||
| Overall | 77 (69–82) | 76 (69–82) | ||
| <70 years | 73 (27%) | 73 (27%) | ||
| ≥70 years | 195 (73%) | 196 (73%) | ||
| Ethnicity | ||||
| White | 251 (94%) | 242 (90%) | ||
| Asian | 12 (4%) | 18 (7%) | ||
| Black | 4 (1%) | 5 (2%) | ||
| Other | 1 (<1%) | 4 (1%) | ||
| Indication for antithrombotic therapy before intracerebral haemorrhage† | ||||
| At least one occlusive vascular disease | ||||
| With atrial fibrillation | 42 (16%) | 50 (19%) | ||
| Without atrial fibrillation | 194 (72%) | 189 (70%) | ||
| No occlusive vascular diseases | ||||
| With atrial fibrillation | 19 (7%) | 23 (9%) | ||
| Without atrial fibrillation | 13 (5%) | 7 (3%) | ||
| History of intracranial or extracranial haemorrhage† | 22 (8%) | 25 (9%) | ||
| Location of intracerebral haemorrhage* | ||||
| Lobar supratentorial | 166 (62%) | 166 (62%) | ||
| Non-lobar | 102 (38%) | 103 (38%) | ||
| Time since intracerebral haemorrhage symptom onset* | ||||
| Overall | 80 (30–149) | 71 (29–144) | ||
| 1–6 days | 10 (4%) | 11 (4%) | ||
| 7–30 days | 59 (22%) | 59 (22%) | ||
| >30 days | 199 (74%) | 199 (74%) | ||
| Probability of good 6-month outcome*19 | ||||
| <0·15 | 48 (18%) | 51 (19%) | ||
| ≥0·15 | 220 (82%) | 218 (81%) | ||
| Context of enrolment | ||||
| Hospital inpatient | 87 (32%) | 96 (36%) | ||
| Hospital outpatient | 181 (68%) | 173 (64%) | ||
| Participant consented | 212 (79%) | 213 (79%) | ||
| Proxy consented | 56 (21%) | 56 (21%) | ||
Data are n (%) or median (IQR).
*
Variables used in the minimisation algorithm.
†
Complete list of comorbidities is in the appendix.